This symposium at ERA 2025 explored the evolving treatment landscape in immunoglobulin A nephropathy (IgAN) and novel, targeted therapies under clinical development. Experts reviewed updated KDIGO guidelines and treatment goals and provided case-based insights and practical strategies to maximise proteinuria reduction and optimise patient care.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles

